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Loss-of-function mutations in parkin are the major
cause of early-onset familial Parkinson’s disease. To in-
vestigate the pathogenic mechanism by which loss of
parkin function causes Parkinson’s disease, we gener-
ated a mouse model bearing a germline disruption in
parkin. Parkin/ mice are viable and exhibit grossly
normal brain morphology. Quantitative in vivo microdi-
alysis revealed an increase in extracellular dopamine
concentration in the striatum of parkin/ mice. Intra-
cellular recordings of medium-sized striatal spiny neu-
rons showed that greater currents are required to in-
duce synaptic responses, suggesting a reduction in
synaptic excitability in the absence of parkin. Further-
more, parkin/ mice exhibit deficits in behavioral par-
adigms sensitive to dysfunction of the nigrostriatal
pathway. The number of dopaminergic neurons in the
substantia nigra of parkin/ mice, however, is normal
up to the age of 24 months, in contrast to the substantial
loss of nigral neurons characteristic of Parkinson’s dis-
ease. Steady-state levels of CDCrel-1, synphilin-1, and
-synuclein, which were identified previously as sub-
strates of the E3 ubiquitin ligase activity of parkin, are
unaltered in parkin/ brains. Together these findings
provide the first evidence for a novel role of parkin in
dopamine regulation and nigrostriatal function, and a
non-essential role of parkin in the survival of nigral
neurons in mice.
Parkinson’s disease (PD)1 is an age-related movement disor-
der characterized by bradykinesia, rigidity, resting tremor, and
postural instability. The neuropathologic hallmarks of PD are
the loss of dopaminergic neurons in the substantia nigra (SN)
and the presence of intraneuronal cytoplasmic inclusions
known as Lewy bodies. The clinical manifestations of PD are
due to progressive degeneration of dopaminergic neurons in the
pars compacta of the SN that give rise to the nigrostriatal
pathway, causing dopamine (DA) depletion in the striatum,
where it is required for normal motor function. Little is known
about the mechanisms of PD pathogenesis and nigral degener-
ation, although DA neurons have been shown to be susceptible
to oxidative stress (1), mitochondrial defects (2), and environ-
mental toxins (3).
The recent identification of genes linked to familial forms of
PD (FPD) makes it possible to investigate the pathogenic mech-
anism by employing genetic approaches (4–6). Over fifty reces-
sively inherited mutations, including deletion, frameshift, non-
sense, and missense mutations, have been identified in parkin
in large numbers of families, making parkin the major gene
responsible for early-onset FPD (7–10). Although the first re-
port linked parkin mutations to autosomal recessive juvenile
parkinsonism (AR-JP) with atypical clinical features (5), many
more cases identified subsequently were considered typical
early-onset FPD with symptoms often indistinguishable from
sporadic PD (9, 11). Autopsies of limited numbers of patients
showed selective loss of dopaminergic neurons in the SN either
in the absence (12–15) or in the presence (16) of Lewy bodies.
The recessive inheritance mode and variety of parkin muta-
tions indicate a loss-of-function pathogenic mechanism.
Parkin is widely expressed in most tissues including brain
and heart (5). Although its transcripts are equally abundant in
various brain sub-regions, parkin protein is enriched in the SN
(5, 17–20). In vitro studies have shown that parkin can function
as an E3 ubiquitin ligase, mediating the covalent transfer of
ubiquitin to protein substrates subject to proteasomal degra-
dation (21–23). However, it is unclear how loss of parkin func-
tion leads to nigral degeneration and PD.
To investigate the pathogenic mechanism of PD in an animal
model and to elucidate the normal physiological role of parkin
in vivo, we created a mouse model bearing a targeted germline
disruption of parkin. Molecular, histological, neurochemical,
electrophysiological, behavioral, and biochemical analyses of
parkin/ mice reveal a novel role for parkin in dopamine
regulation and nigrostriatal function in vivo, and a non-essen-
tial role of parkin in the survival of nigral neurons in mice.
EXPERIMENTAL PROCEDURES
Generation of parkin/ Mice—A targeting vector was constructed
using 1.8- and 3.5-kb DNA fragments as the 5 and 3 homologous
sequences, respectively (Fig. 1A). A negative selection cassette, PGK-dt,
which encodes the diphtheria toxin and has been shown to enhance
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screening efficiency as much as 75-fold (24), was also included. The
linearized targeting vector was transfected into J1 (129/Sv) ES cells.
After selection in G418, 200 clones were screened by Southern analysis
for homologous recombination. Six clones were identified by the pres-
ence of the expected 3.7-kb band corresponding to the targeted allele.
Using the 3 external probe and a probe specific for the neo sequence,
two clones were confirmed to carry the desired homologous recombina-
tion events without random insertion. ES cells of both clones were
injected into C57BL/6 and Balb/c blastocysts. Chimeric offspring were
crossed with C57BL/6 mice to obtain germline transmission, which was
confirmed by Southern analysis with the 5 probe shown in Fig. 1A.
Heterozygous mice were then interbred to obtain homozygous knockout
and wild-type control mice. Mice were subsequently genotyped by PCR
using primers (5-CCTACACAGAACTGTGACCTGG; 5-GCAGAATTA-
CAGCAGTTACCTGG; 5-ATGTTGCCGTCCTCCTTGAAGTCG) spe-
cific for the wild-type or the targeted allele. The resulting 250 and 500
bp PCR products correspond to the wild-type and targeted alleles,
respectively. All experimental procedures were carried out in accord-
ance with the USPHS Guide for Care and Use of Laboratory Animals.
Northern, RT-PCR, and Western—Northern and RT-PCR were per-
formed as previously described (25). For Western blotting, brains were
Dounce-homogenized in buffer (0.33 M sucrose, 8 mM HEPES, pH 7.4,
Roche complete protease inhibitors for parkin, or 150 mM NaCl, 50 mM
Tris, pH 7.4, 0.2% Nonidet P-40, Roche complete protease inhibitors for
-synuclein, synphilin-1 and CDCrel-1) and centrifuged, and the pro-
tein content of the supernatant was analyzed by BCA assay (Pierce).
Immunoprecipitation of -synuclein for detection of the glycosylated
species was performed essentially as previously described (26) with the
following modifications: 10 mg of supernatant was used for the immu-
noprecipitation of -synuclein and the IP antibody (KC7071) was used
at a 1:10 dilution. For Western blotting, 50 g of protein was mixed with
2 Laemmli buffer, boiled, and resolved on 10% acrylamide gels (par-
kin, synphilin-1, and CDCrel-1) or 4–20% gradient gels (-synuclein)
(Invitrogen), transferred to nitrocellulose membranes, blocked in 5%
milk in TBST (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20), and
incubated with a primary antibody (Parkin, Cell Signaling 2132;
1:1000; CDCrel-1, gift of Dr. William Honer, 1:1000; -synuclein, Syn-1,
BD PharMingen, 1:2000; synphilin-1, gift of Dr. Simone Englender,
1:100) and then a peroxidase-conjugated anti-rabbit (parkin, CDCrel-1,
and synphilin-1) or mouse (-synuclein) antibody (Promega). The
membranes were then treated with chemiluminescence reagent
(PerkinElmer Life Sciences) and exposed to film. Samples were rep-
robed with tubulin and actin to confirm equal protein loading.
Histology and Neuron Count—Mouse brains were dissected, formalin
fixed for 2 h, processed for paraffin embedding, and sectioned in the
coronal plane at 16-m thickness. Each paraffin block contained 4
parkin/ and 4 wild-type brains. Deparaffinized sections were
stained with cresyl violet or tyrosine hydroxylase (TH) antibodies. The
number of DA neurons in the SN was determined by counting TH-
immunoreactive neurons in coronal sections of four brains per genotype
per age group using the fractionator and optical dissector methods of
unbiased stereology (27) under a Leica DMRB microscope equipped
with a CCD camera connected to a computer running Bioquant image
analysis software. The same software was used to measure nigral DA
neuron volumes from 4 wild-type and 4 parkin/ brains at the age of
24 months. The experimenter was blind to the genotypes of the mice.
Values are reported as means  S.E. Statistical differences were as-
sessed by Student’s t test.
Striatal DA Measurements—For striatal tissue DA measurement,
striata were dissected and stored at 80 °C. Frozen striata were soni-
cated in ice-cold 0.1 N perchloric acid, 0.2 mM sodium bisulfite and
centrifuged 20 min at 20,000  g at 4 °C to remove debris. The super-
natant was filtered (0.2 m) and applied to a C18 reverse phase HPLC
column linked to an ESA model 5200A electrochemical detector.
For no-net-flux microdialysis, parkin/ and wild-type mice were
implanted unilaterally under halothane anesthesia with a microdialy-
sis probe (CMA 11, 2-mm membrane length, CMA/Microdialysis,
Chelmsford, MA) in the striatum using the following stereotaxic coor-
dinates measured from bregma and the skull surface in mm: rostral
0.6, lateral 1.8, ventral 4.5. Probes were perfused with an artificial
cerebrospinal fluid (ACSF: 0.2 mM ascorbic acid, 125 mM NaCl, 2.5 mM
KCl, 0.9 mM NaH2PO4, 5 mM Na2HPO4, 1.2 mM CaCl2, 1 mM MgCl2, pH
7.4) at a flow rate of 0.5 l/min. After 24 h, DA was incorporated in the
microdialysis perfusion medium at 5 different concentrations (0, 5, 10,
20, 40 nM) each for 2 h in random order and dialysate was collected in
30 min. intervals into 1.5 l of 12.5 mM perchloric acid/250 M EDTA.
Samples were frozen at 70 °C for analysis by HPLC with electrochem-
ical detection (Antec Leyden, Zoeterwoude, The Netherlands) as de-
scribed previously (28). The difference in DA concentration between the
perfusion medium flowing into the probe and that flowing out of the
probe ([DA]in  [DA]out) was plotted on the y-axis against [DA]in on
the x-axis. A line of best fit was constructed by least-squares analysis.
The intercept at the x-axis (DA concentration at the point of no net flux)
and the slope of the line (the extraction fraction, a measure of DA
reuptake) was determined for each animal and differences between
genotypes were assessed by Students’ t test.
Dopamine Receptor Binding Assays—D1 and D2 binding assays were
performed with [3H]spiperone and [3H]SCH23390, essentially as previ-
ously detailed (29) using crude synaptic membrane fractions prepared
from mouse striata (prepared as described in Ref. 30) with ketanserin
(100 nM) included to inhibit binding to 5-HT2A/2C serotonin receptors.
Protein determinations were performed using the BioRad kit with bo-
vine serum albumin as a standard. Binding data were analyzed with
Prism (GraphPad) as previously described (31). Data represent mean 
S.E. of 3–6 separate determinations from striata isolated from wild-
type and parkin/ animals. Statistical differences were assessed by
Student’s t test.
Electrophysiology—Detailed electrophysiological procedures were
previously described (32). Briefly, mice were anesthetized with halo-
thane, decapitated, brains were placed in ice-cold oxygenated ACSF (in
mM: NaCl 130, NaHCO3 26, KCl 3, MgCl2 5, NaH2PO4 1.25, CaCl2 1,
glucose 10 (pH 7.2–7.4)) and coronal corticostriatal sections (350 m)
were made so that striatal neurons could be studied both intracellularly
and by activation of their main excitatory input from the cortex. Slices
were transferred to a submersion recording chamber in which they were
perfused constantly with oxygenated ACSF (31–32 °C) in an atmo-
sphere of warm, moist 95% O2, 5% CO2. Intracellular responses were
recorded using sharp microelectrodes (60–110 MOhms) filled with 3 M
potassium acetate, 5 mM KCl, and 2% w/v biocytin to facilitate subse-
quent examination of the morphology of recorded neurons. Basic pas-
sive and active membrane properties (resting membrane potential
(RMP), current-voltage relationships, input resistance, action potential
(AP) parameters (amplitude and half-amplitude duration), after hyper-
polarization (AHP) amplitude) were examined using intracellularly in-
jected current pulses to determine neuronal excitability. Values are
reported as means  S.E. Synaptic responses were evoked with a
bipolar stimulating electrode placed in the corpus callosum to activate
primarily corticostriatal afferents, the main excitatory pathway into
the striatum, which release glutamate. Stimuli of increasing intensity
(100-s duration) were delivered every 5 s and 5 traces at each intensity
were averaged. Peak amplitudes of postsynaptic potentials (PSPs) were
measured, and input-output relationships were plotted. From each cell,
the averaged PSP whose peak amplitude was 50% of maximum on the
input-output curve was further analyzed for between-group compari-
sons of peak amplitudes and half-amplitude durations. Paired-pulse
facilitation was assessed by presenting two stimuli, which evoked re-
sponses at 50% maximum amplitude 50 ms apart and measuring the
ratio of the peak amplitude of the second PSP divided by the first PSP.
Biocytin labeling confirmed that all recovered neurons were medium-
sized spiny neurons with similar appearance between genotypes.
Behavioral Tests—All tests were performed by investigators blind to
the genotypes. For the open field test, individual mice were placed in
42  42 cm acrylic animal cages for 15 min during which their hori-
zontal and vertical movements were monitored by 3 arrays of 16 infra-
red light beam sensors (AccuScan Instruments) and analyzed using
AccuScan VersaMax software.
For the rotarod test, mice were placed 4 at a time on an Economex
accelerating rotarod (Columbus Instruments) equipped with individual
timers for each mouse. Mice were initially trained to stay on the rod at
a constant rotation speed of 5 rpm. After a 2-min rest, mice that would
fall were repeatedly placed back on the rotarod until they were able to
stay on the rotating rod for at least 2 min. Following training, mice were
subsequently tested by placing them on the rod at a rotation speed of 5
rpm, as the rod accelerated by 0.2 rpm/sec, the latency to fall was
measured. Mice were tested for a total of 3 trials.
For the beam traversal task, a Plexiglas beam (Plastics Zone Inc.,
Woodland Hills, CA) consisting of four sections (25 cm each, 1 m total
length) of varying width (3.5, 2.5, 1.5, and 0.5 cm) was used. To increase
the difficulty of the test, a wire mesh cover (1 cm2) of corresponding
width was placed on the beam surface. Mice were trained for 2 days to
traverse the beam without the wire mesh to their home cages. On the
day of the test, mice were trained further with two trials without the
grid overlay and two trials with the wire grid placed on the beam. Mice
were then tested for 3 trials by traversing the grid-surfaced beam, and
their performance was videotaped. The numbers of steps and slips (a
limb slipped through the wire grid during a forward movement) were
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counted by viewing the videotapes in slow motion. Fisher’s LSD was
used for planned comparisons between genotypes.
For the adhesive removal test, small adhesive stimuli of five increas-
ing sizes were placed on the forehead, out of view for the mice. The
stimuli consisted of 0.25 and 0.5 inch Avery labels cut in half or whole
or combined. To remove the stimulus, mice raised both forelimbs toward
their head and swiped off the stimulus with both forepaws within a 60-s
trial, after which the experimenter removed the adhesive. Each mouse
was given a score equal to the largest size adhesive it was unable to
sense and remove, averaged over two trials. Scores were compared
between genotypes using a Mann-Whitney U test. All mice were able to
sense and remove the largest size adhesive, but none could sense and
remove the smallest adhesive.
RESULTS
Generation of Parkin-deficient Mice—parkin is a large gene
(2 Mb), which contains 12 exons and encodes a protein of 465
amino acid residues (5, 33). The exon 3 deletion mutation is one
of the most common mutations in AR-JP and results in absence
of parkin protein (8, 18, 20). Exon 3 contains a non-integral
number of codons, thus, deletion of exon 3 results in a frame-
shift after amino acid 57 and premature termination at a stop
codon in exon 4 following 39 additional out-of-frame amino acid
residues in humans (8, 18, 20). We therefore chose to target
exon 3 to generate a parkin-null mutant mouse. A targeting
vector was constructed in which most of exon 3 was replaced
in-frame by the coding sequence of EGFP, followed by transla-
tion and transcription termination sequences and the PGK-neo
cassette (Fig. 1A). The protein sequences predicted to result
from wild-type and mutant transcripts are depicted in Fig. 1B.
Two clones of ES cells carrying the proper homologous recom-
bination events without random integration of the targeting
vector were injected into blastocysts. Germline transmission of
the targeted allele was confirmed by Southern analysis (Fig.
1C). Interbreeding of heterozygous mice gave rise to wild-type,
heterozygous, and homozygous knockout (parkin/) mice at
the expected Mendelian ratio.
To determine whether our targeted mutation causes skip-
ping of exon 3, we performed Northern and RT-PCR analyses.
Northern analysis of total RNA using a probe specific for exons
4–12 showed a smaller parkin transcript in parkin/ brains
(Fig. 1D). RT-PCR analysis using primers specific for exons 2
and 5 followed by sequencing confirmed that in parkin/
brains exon 2 was spliced to exon 4, skipping exon 3 entirely
(Fig. 1E). Exon 3 skipping causes a reading frameshift after
amino acid 57 and premature termination at a stop codon in
exon 5 following 49 additional out-of-frame amino acid residues
in mice (Fig. 1B). The sensitivity of RT-PCR confirmed the
complete absence of intact parkin transcripts in parkin/
mice. Sequencing also revealed an aberrant splice product,
which results from the use of a cryptic splice acceptor site 3
bases into exon 4, leading to addition of 48 rather than 49
out-of-frame amino acid residues (Fig. 1B). Although these
truncated parkin transcripts are present in parkin/ mice, it
is unlikely that functional parkin fragments can be produced
from these truncated transcripts. Western analysis using an
antiserum raised against the C-terminal region of parkin con-
firmed the absence of parkin in parkin/ mice (Fig. 1F), and
ruled out the presence of possible parkin fragments initiated
from in-frame ATGs downstream of exon 3, consistent with the
notion that reinitiation of translation following a sizable open
reading frame is highly unlikely (34).
Since we introduced the EGFP cDNA fused in-frame into
parkin exon 3, which was intended for a reporter system for the
parkin promoter activity, we also performed Northern analysis
using an EGFP-specific probe and confirmed the presence of
EGFP transcripts in parkin/ mice (data not shown). RT-
PCR followed by sequencing confirmed that the EGFP coding
sequence is intact and fused in-frame to parkin exon 3. How-
ever, the parkin-EGFP fusion protein was barely detectable by
Western analysis (data not shown), perhaps due to the pres-
ence of the ubiquitin-like domain of parkin (35).
parkin/ mice are viable and fertile without obvious ab-
normalities. Open field tests of parkin/ mice revealed no
significant alterations in their general behavior and explora-
tory anxiety (Fig. 2). Nissl staining revealed normal brain
morphology in parkin/ mice (Fig. 3, A and B). Immunohis-
FIG. 1. Generation and characterization of parkin/ mice. A,
schematic representation of the wild-type parkin genomic region en-
compassing exon 3, indicated by a small open box, and the targeted
allele. The locations of the three probes used for Southern analysis are
indicated, along with the sizes of EcoRV restriction fragments. Abbre-
viations: H, HindIII; N, NdeI; RI, EcoRI; RV, EcoRV. B, schematic
representation of the structure of the expected protein products derived
from the wild-type and the targeted alleles. Amino acid residue num-
bers are shown above relevant domains (shaded gray) or frame-shifted
sequences (hatched). Numbers in boxes depict the exons coding for each
region. C, Southern analysis of tail DNA digested with EcoRV and
hybridized with the 5 probe. D, Northern analysis of total RNA hybrid-
ized with a probe specific for exons 4–12 shows a smaller mRNA species
in parkin/ mice. E, RT-PCR analysis of parkin transcripts using
primers specific for exons 2 and 5. F, Western analysis of total brain
homogenates confirms the reduction and absence of parkin in heterozy-
gous and homozygous mutant mice, respectively. The same blot was
incubated with a -tubulin antibody to normalize loading.
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tochemical analysis of parkin/ brains using antibodies spe-
cific for synaptophysin, Munc-18 and calbindin showed grossly
normal synaptic staining and striatum formation (data not
shown). No inclusions were observed in any brain sub-regions,
including the SN, using antibodies specific for -synuclein and
ubiquitin (data not shown).
Normal Neuroanatomy of DA Neurons in parkin/
Mice—It has been proposed that the reduction in DA neurons
in AR-JP could be due to impaired generation and maturation
of these neurons, based on the observation that the remaining
DA neurons in autopsies of AR-JP patients appear immature
(18). Recently, parkin-null flies have also been shown to exhibit
smaller dopaminergic neurons (36). Immunohistochemical
analysis of parkin/ mice using an antibody specific for TH,
however, revealed normal morphology of DA neurons in the SN
(Fig. 3, C–F) and noradrenaline neurons in the locus ceruleus
(Fig. 3, G and H).
The most prominent neuropathological feature of AR-JP and
PD is the selective loss of dopaminergic neurons in the SN
(12–15). We therefore quantified the number of DA neurons in
the SN of parkin/ (n  4) and control mice (n  4) at 12, 18,
and 24 months using unbiased stereological methods (27). Sim-
ilar numbers of TH-positive neurons were found in the SN of
parkin/ and wild-type mice at 12 (/: 8520  540; /:
8720  710; p  0.05), 18 (/: 8960  450; /: 9360  470;
p  0.05) and 24 months (/: 10500  720; /: 10300 
1180; p  0.05). We also measured the volume of DA neurons
(/: n  47; / n  50) in the SN of 4 mice per genotype at
age 24 months, and found similar neuron volumes between
parkin/ (2702  150 m3) and wild-type (2674  173 m3;
p  0.05) mice.
Increased Extracellular DA in the Striatum of parkin/
Mice—We then looked for alterations in dopamine neurotrans-
mission, which may occur prior to frank loss of dopaminergic
neurons. Dopaminergic projections revealed by TH immunore-
activity appear normal in the striatum of parkin/ mice (Fig.
3, I and J). Striatal levels of DA and its major metabolites,
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA) are similar between parkin/ and control mice at 6,
12, 18, and 24 months (p  0.05) (Fig. 4A). To determine
whether there are alterations in dopamine release or reuptake,
we performed no-net-flux microdialysis (37, 38) in the striatum
of parkin/ and wild-type mice at 8–9 months. When per-
fused with ACSF containing no DA, the dialysate DA concen-
tration in parkin/ mice (n  10) (10.8  1.2 nM) was signif-
icantly higher than that in wild-type mice (n  10) (7.7  0.4
nM; p 	 0.02) (Fig. 4B).
The concentration of DA at the interpolated point of no-net-
flux, a measure of extracellular DA concentration, was also
significantly higher in parkin/ mice (n  10) (24.2  1.2 nM)
relative to wild-type controls (n  9) (20.2  0.9 nM; p 	 0.02)
(Fig. 4, C and D). The data from one wild-type mouse (indicated
by an arrow in Fig. 4C), which met the statistical standard as
an outlier (39), was excluded. The extraction fraction, a meas-
ure of DA reuptake, was not significantly different between
wild-type (0.39  0.04) and parkin/ (0.46  0.05; p  0.05)
mice (Fig. 4E). The elevated level of extracellular DA in par-
kin/ mice, therefore, likely results from increased release of
dopamine.
Unchanged Levels and Binding Affinities of D1 and D2 Re-
ceptors in the parkin/ Striatum—We then examined
whether the increase in extracellular DA results in an alter-
ation of striatal DA receptors. Similar total receptor binding
was found for both D1 and D2 receptors in the striatum of
FIG. 2. Open field test. parkin/ and wild-type mice exhibit sim-
ilar levels of horizontal activity (A) and stereotypy (B) in 15-min trials.
FIG. 3. Normal neuroanatomy in parkin/ brains. A and B,
Nissl-stained coronal brain sections at the level of the SN. C and D,
higher power views of the boxed area in A, B showing normal TH
immunoreactivity in the SN. E and F, higher power views of the boxed
area in C and D showing normal morphology of dopaminergic neurons.
G and H, similar TH immunoreactivity in the locus ceruleus. I and J,
similar TH immunoreactivity in the striatum. Scale bar: 0.05 mm.
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parkin/ and control mice (Bmax [fmol/mg], D1: 308  65
versus 236  34, D2: 347  82 versus 328  54 in / and /,
respectively; n  6 for D1, p  0.35; n  3 for D2, p  0.85).
Examination of binding kinetics for D1 and D2 receptors sim-
ilarly revealed no alterations in the affinity of either receptor
(Kd [nM], D1: 1.60  0.34 versus 1.06  0.21, D2: 1.80  0.46
versus 1.64  0.32 in / and /, respectively; n  6 for D1,
p  0.21; n  3 for D2, p  0.95). These results suggest that
there are no significant changes in DA receptor levels or bind-
ing affinities in parkin/ mice, despite the increased extra-
cellular concentration of DA.
Loss of parkin Decreases Synaptic Excitability of Striatal Neu-
rons—The significant increase in extracellular DA in the stria-
tum of parkin/ mice prompted us to examine the electrophysi-
ological responses of striatal neurons, as previous studies have
demonstrated that the excitability of these neurons is strongly
influenced by DA levels (40, 41). We focused our analysis on the
medium-sized spiny neurons, which are the major neuronal sub-
type in the striatum. Major inputs received by these neurons
include glutamatergic excitatory inputs from the cortex and do-
paminergic inputs from the SN. Acute coronal corticostriatal
slices were prepared from parkin/ mice (n  7) and wild-type
controls (n  6) at 6–9 months of age and striatal neurons (/:
n  13, /: n  10) were examined by injecting current pulses
intracellularly into each neuron (Fig. 5A). No significant differ-
ences in passive and active membrane properties were observed
between the genotypes and all values were in the range of those
reported in the literature for medium-sized spiny neurons (RMP:
78  3 versus 80  2 mV; input resistance: 29  5 versus 37 
5 MOhms; AP amplitude: 66  3 versus 68  3 mV; AP width at
1/2 amplitude: 0.76  0.03 versus 0.75  0.07 ms; AHP ampli-
tude: 11.7  1.4 versus 12.1  1.0 mV in / versus / neurons,
respectively) (Fig. 5A).
We then examined the synaptic response of the medium-
sized spiny neuron by stimulation of corticostriatal afferents,
the major glutamatergic excitatory pathway into the striatum.
Although parkin/ (n  13) and wild-type (n  10) neurons
exhibited similar mean amplitudes and durations of evoked
synaptic responses (peak amplitude: 9.9  0.8 versus 10.5  0.7
mV; peak duration at 1/2 amplitude: 9.05  0.46 versus 9.22 
0.56 ms for / versus / neurons, respectively) (Fig. 5B),
higher currents were needed to evoke similar responses in
parkin/ neurons relative to the wild-type, as indicated by
the significant rightward shift in the input-output relation-
ships (p 	 0.02) (Fig. 5C). The current required to evoke action
potentials synaptically in parkin/ neurons (n  10; 720 
163 A) was also significantly higher than in wild-type controls
(n  12; 202  53 A) (p 	 0.004). These findings suggest that
medium-sized striatal neurons are less excitable synaptically
in parkin/ mice. There were no differences in paired-pulse
facilitation (50 ms interpulse interval) between wild-type
(0.98  0.06) and parkin/ (1.02  0.57) neurons, suggesting
that the observed synaptic defect in parkin/ mice may be
caused by a postsynaptic alteration.
Behavioral Impairments in parkin/ Mice—We further
tested parkin/ mice for possible alterations in motor activ-
ities using a beam traversal task, which is sensitive to impair-
ment in the nigrostriatal pathway (42–45). Planned compari-
sons revealed that parkin/ mice performed significantly
worse than wild-type controls with higher numbers of slips and
slips per step at all age groups (p 	 0.05), while the number of
steps was similar between the genotypic groups (Fig. 6, A–C).
We further evaluated these mice in the rotarod task (46), which
is commonly used to score severe motor impairments in ro-
dents. parkin/ and control mice exhibited similar latencies
for remaining on the rotating rod (Fig. 6D).
Another test sensitive to nigrostriatal dysfunction in rodent
models is the adhesive removal test, which assesses somato-
sensory abilities (47–49). parkin/ mice at 2–4 and 7 months
performed significantly worse compared with wild-type con-
trols (p 	 0.05), though the difference at 18 months was not as
marked, likely due to the age-dependent decline of wild-type
mice (Fig. 6E). Only 63% of wild-type mice at 18 months re-
moved the middle size stimulus, compared with 100% at 4
months. This result is consistent with a previous report show-
ing poorer performance by older animals (50).
Unchanged Levels of parkin Substrates—Recent in vitro
studies have shown that parkin functions as an E3 ubiquitin
ligase (21–23,26,51–54). Several proteins, such as CDCrel-1,
synphilin-1, and glycosylated -synuclein, have been shown to
be ubiquitinylated by parkin in vitro. We therefore examined
whether loss of parkin function results in accumulation of these
proteins in parkin/ mice. Western analysis showed similar
levels of CDCrel-1, synphilin-1, and -synuclein in parkin/
and wild-type control brains (Fig. 7, A–C). Immunoprecipita-
tion of -synuclein followed by Western blotting using a second
-synuclein-specific antibody revealed the presence of an addi-
tional low abundance isoform at 22 kDa, consistent with the
apparent molecular weight of the glycosylated isoform of
-synuclein previously reported as a parkin substrate (26). No
differences were observed in the steady state level of this
higher molecular weight species between the genotypes (Fig.
7D). These results indicate that loss of parkin function does not
affect the stead state level of any of these proteins in the mouse
brain.
FIG. 4. Increased extracellular DA in the striatum of parkin/
brains (A) HPLC quantification of striatal tissue content of DA. Values
shown are means  S.E. of parkin/ and wild-type controls (4 per
genotype for ages of 6 and 12 months, 7 per genotype for 18 months, 10
parkin/ and 4 wild-type for 24 months). B, dialysate DA concentra-
tion following perfusion with DA-free ACSF. Bars show means  S.E.
for 10 parkin/ and 10 wild-type mice (asterisk; p 	 0.02, Student’s t
test). C, extracellular DA concentration determined by the point of
no-net-flux for each mouse with a single statistical outlier in the wild-
type group highlighted by the arrow. D, extracellular DA concentration
(means  S.E.) for 10 parkin/ and 9 wild-type mice (asterisk; p 	
0.02, Student’s t test). E, extraction fractions determined by the slope of
the linear regression line for each mouse. Bars show means  S.E. for
10 parkin/ and 9 wild-type mice (p  0.05).
Nigrostriatal Dysfunction in Parkin-deficient Mice43632
DISCUSSION
Despite a large body of evidence linking loss-of-function mu-
tations of parkin to FPD, the normal physiological role of par-
kin and the mechanism by which parkin mutations cause ni-
gral degeneration are unknown. Here we present three
independent lines of evidence supporting a novel role of parkin
in the nigrostriatal pathway. First, the extracellular DA con-
centration is significantly increased in the striatum of par-
kin/ mice, which is likely due to an increase in dopamine
release from nigral neurons. Second, the synaptic excitability of
medium-sized spiny striatal neurons is reduced, as evidenced
by increased currents required to evoke synaptic responses and
action potentials. Lastly, parkin/ mice exhibit deficits in
behavioral tasks previously shown to be sensitive to nigrostria-
tal dysfunction (42–45, 47–49, 55, 56), although we cannot
exclude the possibility that alterations in other neural circuits
may also contribute to the observed behavioral deficits.
Together, these results indicate that parkin loss-of-function
mutations cause defects in both DA release from nigral neurons
and synaptic excitability of medium-sized spiny striatal neu-
rons, which are the major target of nigral dopaminergic projec-
tions. Previous studies have shown that DA decreases gluta-
FIG. 5. Electrophysiological deficits in parkin/ mice. A, current-voltage relationship of medium-sized striatal neurons recorded in acute
slices, which was generated by injecting current pulses into each neuron and recording the change in induced voltages. No significant differences
are found in current-voltage relationships or average passive and active membrane properties between parkin/ and control neurons. Numbers
to the left are RMPs for the two cells shown. B, depolarizing synaptic responses evoked by stimulation of corticostriatal afferents (arrows indicate
the time of stimulation). Traces show no differences between the genotypes in superimposed representative response curves at 20, 50, and 80%
of the maximum amplitude (each curve is the average of at least 5 traces). C, normalized input-output relationship. Filled circles represent the
intensity of the stimulation current (mean  S.E.) needed to evoke responses at 20, 50, and 80% of the maximum postsynaptic potential in
parkin/ (n  13) and wild-type (n  10) neurons. Group differences at 50% (p 	 0.03) and 80% (p 	 0.003) were statistically significant (analysis
of variance followed by post-hoc Student’s t tests).
FIG. 6. Behavioral deficits in parkin/ mice. A, slips; B, slips per step; and C, steps while traversing a narrowing mesh-covered beam. At
ages 2–4 (/: n  9, /: n  9), 7 (/: n  10, /: n  9) and 18 months (/: n  7, /: n  9), parkin/ mice had significantly more
slips and slips per step compared with wild-type controls (asterisks; p 	 0.05, Fisher’s LSD). Values are means  S.E. D, Rotarod performance is
shown as the latency to fall off an accelerating rotating rod. The mean  S.E. is shown for wild-type and parkin/ mice at ages 6, 12, and 18
months (n  8 per genotype at each age). E, somatosensory abilities scored according to the largest of five increasing sizes of adhesive that could
not be detected and removed. Smaller numbers represent better performance. Mean scores are shown  S.E. Pair-wise comparison of wild-type and
parkin/ mice within each age group shows significant impairment of parkin/ mice at ages 2–4 (/: n  9, /: n  9) and 7 months (/:
n  15, /: n  14) (asterisks; p 	 0.05, Mann-Whitney U) but not at 18 months (/: n  8, /: n  9).
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mate release and striatal excitability via activation of pre- and
post-synaptic D2 family of dopamine receptors (41, 57), sug-
gesting that the decreased excitability of striatal neurons in
parkin/ mice could be a consequence of the increased extra-
cellular DA level in the striatum. The observation that parkin
interacts with CASK via its PDZ-domain binding motif and
associates with components of the glutamate receptor-signal-
ing complex, such as PSD-95, NMDAR NR2B subunit, and
CaMKII (58), also suggests a possible role for parkin in the
regulation of synaptic transmission and plasticity. Several pro-
teins that are enriched in presynaptic fractions, including CD-
Crel-1 (23), synphilin-1 (51), and -synuclein (26), have been
described in vitro as substrates for parkin-mediated ubiquiti-
nylation. Although we did not observe an increase in the
abundance of these substrates in parkin/ brains (Fig. 7),
parkin-mediated ubiquitinylation may regulate their activi-
ties in the synapse, possibly resulting in the observed synaptic
phenotypes.
The cardinal neuropathological feature of PD, profound loss
of dopaminergic neurons in the SN, is absent in parkin/
mice. Thus, the mechanism underlying the mild motor deficits
observed in parkin/ mice may differ from the movement
disorder characteristic of PD, which results primarily from
substantial loss of DA neurons. Our results, however, are con-
sistent with other mutant mice that exhibit decreased perform-
ance in beam traversal and increased concentrations of striatal
DA (43). Mouse models of neurodegenerative diseases have
previously been observed to recapitulate some aspects of the
disease in the absence of substantial neuronal loss in the af-
fected brain subregions. Transgenic mice overexpressing wild-
type and FPD-linked mutant human -synuclein exhibit motor
deficits in the absence of loss of DA neurons (59–63). Similarly,
genetically engineered mouse models of Alzheimer’s (64) and
Huntington’s diseases (65) have successfully reproduced be-
havioral and neuropathological aspects of these diseases
largely without recapitulating the cortical and striatal neuro-
nal loss, respectively.
The fact that loss of parkin function alone in mice is insuf-
ficient to cause substantial loss of dopamine neurons suggests
that other factors also contribute to nigral degeneration. One
possibility is that parkin protects neurons from various insults,
which has been observed by overexpressing parkin in trans-
fected cells (66, 67) and transgenic flies (68). However, no
decrease in DA neuron survival has been observed in Drosoph-
ila in which endogenous parkin has been inactivated (36) or
partially inactivated by RNAi (68), consistent with our findings
in parkin/ mice. Together, these findings suggest that ad-
ditional events may be required for neuronal degeneration.
This notion is also consistent with the fact that the age of onset
for FPD patients carrying parkin mutations ranges from juve-
nile to elderly and varies by as much as 20 years even within
single families (9). Other possibilities, including higher toler-
ance to neuronal degeneration in the mouse DA neuron,
shorter life span of mice, and the well-controlled environment
in which these mice are housed, may also contribute to the
absence of the profound nigral degeneration characteristic of
PD brains.
In summary, our findings provide important insights into the
normal physiological role of parkin in dopamine regulation and
nigrostriatal function, which will facilitate the exploration of
the mechanisms of PD pathogenesis and may assist the iden-
tification of novel preventative and therapeutic strategies.
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